Enveric Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.43 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.40M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Details
| Name | Enveric Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 6 |
| Founded | 1994 |
| Ceo | Joseph Tucker |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US29405E5050 |
| Cusip | 29405E505 |
| Cik | 890821 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | Chief Executive Officer and Director |
| Kevin M. Coveney CPA | Chief Financial Officer |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
Contact
| Address | 245 First Street, Riverview II, Cambridge, Massachusetts 02142, United States |
| Phone | 617 444 8400 |
| Website | https://www.enveric.com |